مرجع دارویی
Empagliflozin-linagliptin-metformin
Empagliflozin-linagliptin-metformin is a medicine in the class gastrointestinal tract. It is used for diabetes mellitus.
- گروه دارویی: Gastrointestinal Tract
- موارد مصرف: diabetes mellitus
آخرین به‌روزرسانی
ویژه کادر درمان — فقط جهت مرجع. این صفحه خلاصه‌ای کوتاه است، توصیه پزشکی نیست و جایگزین بروشور رسمی یا قضاوت بالینی نمی‌شود. پیش از تجویز یا تحویل دارو همیشه بررسی کنید.
محتوای بالینی این صفحه فقط به زبان انگلیسی موجود است.
نکات کلیدی
- گروه دارویی
- Gastrointestinal Tract
- شکل‌های دارویی رایج
- قرص
- قدرت‌های رایج
- 1000 mg
- نام‌های تجاری
- 7
- کشورها و بازارها
- 2
موارد مصرف
نحوه اثر
Empagliflozin: SGLT2 inhibitor; SGLT2 is expressed in the proximal renal tubules and is responsible for the majority of the reabsorption of filtered glucose from the tubular lumen; SGLT2 inhibitors reduce glucose reabsorption and lower the renal threshold for glucose, thereby increasing urinary glucose excretion
دوز معمول بزرگسالان (خلاصه برچسب)
Type 2 Diabetes Mellitus: Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus (T2DM)
بارداری و شیردهی
- بارداری
- Unsafe Based on animal data showing adverse renal effects from empagliflozin, use is not recommended during the second and third trimesters of pregnancy
- شیردهی
- Unsafe Since human kidney maturation occurs in utero and during the first 2 years of life when lactational exposure may occur, there may be risk to the developing human kidney, advise patients that use is not recommended while breastfeeding
عوارض جانبی گزارش‌شده
- Nasopharingitis
- Constipation
- Gastroenteritis
- Urinary tract infections
- Hypoglycaemia
- Diarrhea
هشدارهای جعبه سیاه
- Postmarketing cases of metformin-associated lactic acidosis have resulted in death, hypothermia, hypotension, and resistant bradyarrhythmias Onset of metformin-associated lactic acidosis is often subtle, accompanied only by nonspecific symptoms (eg, malaise, myalgias, respiratory distress, somnolence, abdominal pain) Metformin-associated lactic acidosis was characterized by elevated blood lactate levels (>5 mmol/L), anion gap acidosis (without evidence of ketonuria or ketonemia), an increased lactate/pyruvate ratio, and metformin plasma levels generally >5 mcg/mL Risk factors include…
موارد منع مصرف
- Hypersensitivity to empagliflozin, linagliptin, metformin, or any of the excipients in the product
- Metabolic acidosis, including diabetic ketoacidosis
- Severe renal impairment (eGFR <30 mL/min/1.73 m2), ESRD, or dialysis
چه کسانی باید احتیاط کنند
- Serious hypersensitivity reactions, (eg, angioedema) in patients treated with empagliflozin reported postmarketing; discontinue therapy and treat promptly if it occurs per standard of care
- There have been reports of acute pancreatitis, including fatal pancreatitis; if pancreatitis suspected, promptly discontinue
- Heart failure observed with 2 other DPP-4 inhibitors; consider risks and benefits in patients with known risk factors for heart failure; monitor for signs and symptoms
بارداری یا شیردهی، بیماری کلیه یا کبد، آلرژی‌ها و هر داروی یا مکمل دیگری را که مصرف می‌کنید به داروساز یا پزشک خود اطلاع دهید.
ویژه اعضای Pro+
باز کردن کل صفحه
یک حساب بسازید و دوره آزمایشی Pro+ را شروع کنید تا تک‌نگاری کامل Empagliflozin-linagliptin-metformin را ببینید: دوزها، بارداری و شیردهی، عوارض جانبی، هشدارها و همه تداخل‌ها.
- Dosing by age, kidney and liver function, and further dose lines
- Renal and hepatic dose adjustments
- Paediatric dosing
- How to give it
- Pharmacokinetics
- Patient counselling points
- Food interactions
Pro+ را ۱۴ روز رایگان در وب امتحان کنید. بدون نیاز به کارت.
داروهای دیگر همین گروه
پرسش‌های متداول
What is Empagliflozin-linagliptin-metformin used for?
Empagliflozin-linagliptin-metformin is a medicine in the class gastrointestinal tract. It is used for Diabetes mellitus.
What side effects have been reported with Empagliflozin-linagliptin-metformin?
Nasopharingitis, Constipation, Gastroenteritis, Urinary tract infections, Hypoglycaemia, Diarrhea. Serious warning: Postmarketing cases of metformin-associated lactic acidosis have resulted in death, hypothermia, hypotension, and resistant bradyarrhythmias Onset of metformin-associated lactic acidosis is often subtle, accompanied only by nonspecific symptoms (eg, malaise, myalgias, respiratory distress,…
Can Empagliflozin-linagliptin-metformin be taken in pregnancy or while breastfeeding?
Pregnancy: Unsafe. Based on animal data showing adverse renal effects from empagliflozin, use is not recommended during the second and third trimesters of pregnancy Breastfeeding: Unsafe. Since human kidney maturation occurs in utero and during the first 2 years of life when lactational exposure may occur, there may be risk to the developing human kidney, advise patients that use is not recommended while breastfeeding
What does Empagliflozin-linagliptin-metformin interact with?
MediHelp does not list a checked interaction for Empagliflozin-linagliptin-metformin yet. Always tell your pharmacist about every medicine you take.
تک‌نگاری کامل، دوزاژ و بررسی تداخل دارویی در برنامه MediHelp
مرجع کامل را باز کنید، تداخل چند دارو را بررسی کنید و از ابزارهای دوز در برنامه MediHelp استفاده کنید.
